Small-molecule drug combinations promise durable efficacy and improved patient survival across cancer indications while managing toxicity by decreasing the dosages of individual combination partners. However, finding synergistic combination partners while retaining a safe therapeutic window remains a major challenge limited by preclinical experimental capabilities not addressing the complexity of combining hundreds of drugs in a dose dependent manner, and treating heterogeneous patient populations.